Zoetis EBIT Margin
The EBIT Margin (Operating Margin) of Zoetis (ZTS) as of Jul 24, 2026 is 38.00 %. In the previous year, EBIT Margin (Operating Margin) was 36.65 % — a change of 3.68% (higher).
Get this data via API
Financial Data API
EBIT Margin
38.00 %
YoY
3.68%
Last updated:
EBIT Margin (Operating Margin) of Zoetis is 2026 38.00 % . EBIT Margin (Operating Margin) of Zoetis was 2025 36.65 % . It decreases by 3.68% higher compared to the previous year.
Zoetis's operating (EBIT) margin stands at 38.0%, up from 36.0% several years earlier.
Access this data via the Eulerpool API
Zoetis Stock analysis
What does Zoetis do? Zoetis Inc. is a leading company in the development and marketing of animal health technology and solutions. The company specializes in innovative products for animals such as dairy cattle, pigs, poultry, dogs, cats, and horses.
Zoetis was founded in 1952 as a subsidiary of Pfizer and operated as Pfizer Animal Health. In 2013, the company was finally spun off from Pfizer and became Zoetis Inc.
Zoetis focuses on the development, manufacturing, and marketing of products for livestock and pets, including vaccines, pharmaceuticals, biological therapies, and diagnostics. The company operates globally and has its headquarters in Parsippany, New Jersey.
Zoetis' business model consists of various business segments divided into animal categories: cattle, pigs, poultry, pets, and horses. Each of these business segments offers specialized solutions for animal owners and veterinarians.
In the cattle products segment, Zoetis offers products for dairy cows, beef cattle, and calves. They also provide a variety of prevention and treatment solutions for major animal health issues such as mastitis, reproductive disorders, and respiratory problems.
In the swine segment, Zoetis offers prevention and treatment solutions for infectious diseases and parasite control. They also provide products for promoting swine health and weight gain.
In the poultry segment, Zoetis offers solutions for the prevention and treatment of infectious diseases. The company's products aim to improve animal health, productivity, and efficiency.
Zoetis also offers products for the pet segment, including vaccines, pharmaceuticals, and therapies for dogs, cats, and other pets. Here, the company also provides solutions for major health issues such as heart diseases, pain management, and parasite control.
In the horse segment, Zoetis offers solutions for the prevention and treatment of diseases such as equine rhinopneumonia, worm infestations, and arthritis. They also provide products for promoting horse health and performance.
Zoetis is known for a variety of innovative products used by animal owners and veterinarians worldwide. One example is ScourGuard® 4KC, a vaccine that protects calves from diarrheal diseases caused by common bacteria. This vaccine has already proven to be highly effective in controlling bowel diseases in calves.
Zoetis has also developed and marketed the first FDA-approved product for pain management in dogs (Rimadyl®), as well as the first licensed product for the treatment of giardia in dogs (Panacur®).
In summary, Zoetis, as a global leader in the animal health industry, puts innovation and quality at the forefront. With a wide range of products and solutions in various animal categories, Zoetis is a key player in the animal health industry. Zoetis is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Zoetis stock
EBIT Margin (Operating Margin) of Zoetis is 38.00 % in 2026.
Access this data via the Eulerpool API
Margins — Zoetis
All Key Metrics — Zoetis
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth